CLLS Stock Summary and Trading Ideas (Cellectis S.A. - American Depositary Shares | NASDAQ:CLLS)

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.

As of May 13, 2024, CLLS stock price declined to $2.99 with 1,411 million shares trading.

CLLS has a beta of 5.87, meaning it tends to be more sensitive to market movements. CLLS has a correlation of 0.33 to the broad based SPY ETF.

CLLS has a market cap of $215.14 million. This is considered a Small Cap stock.

Last quarter Cellectis S.A. - American Depositary Shares reported $2 million in Revenue and -$.57 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.35.

In the last 3 years, CLLS stock traded as high as $16.86 and as low as $.96.

The top ETF exchange traded funds that CLLS belongs to (by Net Assets): APIE, AVDE.

CLLS has outperformed the market in the last year with a price return of +55.7% while the SPY ETF gained +28.0%. However, in the short term, CLLS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.3% vs +4.4% return in SPY. But in the last 2 weeks, CLLS shares have fared better than the market returning +19.3% compared to SPY +2.6%.

CLLS support price is $2.88 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS stock will trade within this expected range on the day.